Improved cellular and humoral immunity upon a second BNT162b2 and mRNA-1273 boost in prime-boost vaccination no/low responders with end-stage renal disease
- 4 October 2021
- journal article
- letter
- Published by Elsevier BV in Kidney International
- Vol. 100 (6), 1335-1337
- https://doi.org/10.1016/j.kint.2021.09.015
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Impaired Humoral but Substantial Cellular Immune Response to Variants of Concern B1.1.7 and B.1.351 in Hemodialysis Patients after Vaccination with BNT162b2Journal of the American Society of Nephrology, 2021
- Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccineThe Lancet Regional Health - Europe, 2021
- Superior cellular and humoral immunity toward SARS-CoV-2 reference and alpha and beta VOC strains in COVID-19 convalescent as compared to the prime boost BNT162b2-vaccinated dialysis patientsKidney International, 2021